Article Text

Download PDFPDF

CASE REPORT
Fulminant hepatic failure in the setting of progressive ANCA-associated vasculitis associated with a rare alpha-1 antitrypsin phenotype, ’PiEE'
  1. Ronald Reilkoff1,2,
  2. Laurel Stephenson1
  1. 1 Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
  2. 2 Critical Care, Fairview Southdale Hospital, Edina, Minnesota, USA
  1. Correspondence to Dr Ronald Reilkoff, rreilkof{at}umn.edu

Summary

Abnormalities in alpha-1 antitrypsin (AAT) proteins are risk factors for human disease. While the most common is AAT deficiency, a genetic disorder associated with chronic obstructive pulmonary disease, additional disorders associated with AAT abnormalities are increasingly recognised. We describe a middle-aged woman who presented with fulminant hepatic and multiorgan failure. Evaluation revealed the patient to have a rare AAT phenotype PiEE. Her clinical presentation was consistent with antineutrophilic cytoplasmic antibody-associated vasculitis, and her history suggested features of panniculitis. This is the first description of this rare homozygous AAT phenotype and possible disease associations with the ’E' protein. Given that abnormal AAT are under-recognised, and that new mutations and phenotypes continue to be identified, we will need to expand on our knowledge base and report clinical manifestations associated with these abnormal phenotypes.

  • vasculitis
  • intensive care
  • genetics
  • hepatitis other

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors RR was attending for the patient. RR and LS contributed equally to literature review, creation and editing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests RR is on Speaker’s Bureau for Grifols.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.